anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute vertebrobasilar artery occlusion is one of the cerebrovascular diseases with high disability and mortality rates. Although mechanical thrombectomy has recently been demonstrated an effective treatment for large vessel occlusions of posterior circulation, the treatment strategies depending on the specific pathophysiology. Tandem occlusion in posterior circulation is less frequently than in anterior one, comprises severe stenosis or occlusion of the extracranial vertebral artery ipsilateral to its intracranial and basilar occlusion. The recent studies showed the benefit of the "distal-to-proximal" approach, there were many tecniques to achieved the successful recanalization. Besides, the use of Dotter technique allowed 8F guiding catheter to cross the extracranial lesions easily and save the procedural time. However, the Diagnosis 5F-Dotter, like the Dilator-Dotter, has not been mentioned in previous studies. Therefore, the aim of the our study was to assess the improvement of outcomes at 3 months posttreatment in patients receiving rescue extracranial vertebral stenting
This article highlights a selection of important nephrology studies published in 2023 that have relevance for nonnephrologist physicians. Four studies examined progression of chronic kidney disease or cardiovascular disease with respect to finerenone use, magnesium supplementation, iron markers, and COVID-19. Two studies examined treatments to improve specific aspects of chronic kidney disease management, including daprodustat to address anemia and patiromer to address hyperphosphatemia. One study showed that acetazolamide added to loop diuretics increased diuresis in acute decompensated heart failure across a wide range of renal function. Another study found that once-daily hydrochlorothiazide did not prevent kidney stone recurrence. Finally, an antibiotic stewardship intervention safely reduced antibiotic prescribing for suspected urinary tract infection in frail older adults.
<P>PROBLEM TO BE SOLVED: To provide methods to prepare peptides containing epitopes which have enhanced ability to effect an immune response with respect to corresponding analogous wildtype epitopes.  <P>SOLUTION: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes. A method to enhance the immunogenicity of a peptide containing an epitope is also provided. Further, a composition is provided which comprises at least one peptide including Class I epitopes obtained by the above method.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Esters and amides of 9-cis-retinoic acid are synthesized, formulated into pharmaceutically acceptable carriers and administered for the treatment of acne vulgaris, cystic acne, hyperpigmentation, hypopigmentation, psoriasis, dermal and epidermal hypoplasia and kerotoses, the reduction of wrinkling of the skin as an incident of aging and actinic damage, normalization of the production of sebum, the reduction of enlarged pores, promoting the rate of wound healing, limiting of scar tissue formation during healing and the like. They are additionally useful for treatment or amelioration of the same additional classes of skin disorders as is retinoic acid itself and other retinoids. These disorders include ichthyoses (e.g., ichthyosis hystrix, epidermolytic hyperkeratosis, and lamellar ichthyosis), follicular disorders (e.g., pseudofolliculites, senile comedones, nevus comidonicas, and trichostatis spinulosa), benign epithelial tumors (e.g., flat warts, trichoepithelioma, and molluscum contagiosum), perforated dematoses (e.g., elastosis perforans seripiginosa and Kyrles disease), and disorders of keratinization (e.g., Dariers disease, keratoderma, hyperkeratosis plantaris, pityriasis rubra pilaris, lichen planus acanthosis nigricans, and psoriasis). The esters and amides of 9-cis-retinoic acid are also effective for the non-irritating treatment of effects attributable to aging and particularly to photodamage and photoaging. The use of these compounds extends to non-irritating treatments involving the retardation and reversal of additional dermal and cosmetic conditions which are ameliorated by tretinoin such as the effacement of wrinkles, improvement in appearance, namely color and condition of the skin, spots caused from exposure to the sun as well as other skin disorders. The esters and amides of 9-cis-retinoic acid are exceptionally active when compared to other retinoids employed for such indications, and are also exceptionally safe in effective therapeutic doses in contrast to other retinoids.
FIELD: medicine.SUBSTANCE: group of inventions refers to nuclear medicine. A kit for preparing a suspension of polypeptide biodegradable microparticles for radiosynovectomy in isotonic 0.9 % aqueous solution of sodium chloride labeled with a rhenium isotope consists of auxiliary reagents: antioxidant – ascorbic acid in amount of 7 mg, rhenium reducing agent to lower valence state – stannous chloride dihydrate – 11.4 mg, emulsifier – polysorbate-80 – 1.25 mg, polypeptide carrier of radionuclides – microspheres of human blood albumen with diameter of 5–10 mcm – 5 mg, a transchelator and a pH stabilizer – K,Na-tartrate (tartrate K, Na) – 10 mg, wherein all auxiliary reagents are packaged in three bottles: in bottle No. 1 contains a mixture of a reducing agent and an antioxidant, in bottle No. 2 there is a mixture of a polypeptide carrier of radionuclide and emulsifier atoms, bottle No. 3 contains a transchelator and a pH stabilizer, wherein the contents of each flask are sterile and lyophilised. Also disclosed is a sequential three-stage method of producing a suspension of polypeptide biodegradable microparticles for radiosynovectomy.EFFECT: group of inventions provides treating inflammatory joint diseases.4 cl, 4 tbl
Disseminated fungal infection is a major cause of morbidity and mortality in immunocompromised children. Many of the drugs used for fungal prophylaxis have been associated with kidney and liver toxicity. Also, breakthrough infections have been reported with the use of some of the oral agents due to poor oral absorption. An alternative approach is the use of intravenous micafungin for fungal prophylaxis. Micafungin has a distinct advantage due to its better safety profile, specifically in terms of liver and kidney toxicity. Currently, children who receive micafungin are given daily dosing. This study will examine the pharmacokinetics of micafungin when it is given on an every other day schedule. It will examine whether every other day micafungin will provide drug exposure equivalent to daily dosing while reducing administration costs and improving patient convenience. Both animal and adult human data support the use of this approach. Fifteen patients will be enrolled on this study and will be given a single dose of micafungin (3 mg/kg). Blood samples will be drawn for pharmacokinetic measurements after administration of micafungin.
The placebo utilized in the study consisted of the same ingredients as the treatment drink, with the exception of 0.25% Korean wild Ginseng Extract. This was achieved by incor-porating 0.25% scented ginseng and 0.06% caramel coloring (Table 1).
Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
Cohort D received three IM vaccination of 15 mcg CTH522-CAF01 (Day 0, 28, and 112). This cohort was divided into two groups: Cohort D1 received TO placebo given on Day 28, 112, and 140, while cohort D2 received ID placebo given on Day 28 and 112 and TO unadjuvanted CTH522 on Day 140.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, surgery, hepatology. A laparotomy is performed, the inferior mesenteric vein is catheterized. A catheter is passed to the level of the lobar division of the portal vein, determined by palpation of the hepato-duodenal ligament. The catheter is fixed with a ligature in the lumen of the inferior mesenteric vein. The distal catheter is passed retroperitoneally and connected to the port-system chamber, placed subcutaneously in the left hypochondrium and fixed to the aponeurosis of the external oblique abdominal muscle through a separate skin incision. The venous port-system established in this way is used for long-term repeated injections of chemotherapy drugs.EFFECT: allows for long-term and renewable regional chemotherapy of malignant liver tumors, ensures the prevention of arterioportal fistulas, excludes trauma to the main bile ducts and large vessels, as well as hemorrhagic complications due to reliable fixation of the catheter.1 cl, 1 dwg, 1 ex
<P>PROBLEM TO BE SOLVED: To provide a composition and a method for the treatment and prevention of various causal agents which are sexually transmitted.  <P>SOLUTION: For example, mucosal transmission of an antigen using a replicate defective gene delivery vehicle (especially, a replicate defective alphavirus vector and particles) is described. A composition containing a mucosal adjuvant and at least an antigen derived from HIV is also described. The use of these gene transmission vehicles at the induction of mucosal immunity response, local immunity response, and/or general immunity response after mucosal immunity regimen is provided. This invention includes a method of producing immunity response against an antigen. In a specific embodiment, this method includes a process of mucosal administration of a replicate defective gene transmission vehicle (or a vector) containing a polynucleotide coding at least an antigen (or its modified embodiment) to the target cell of the body under test, and here the antigen can stimulate immunity response in the body under test.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention relates to application of transferrin receptor 1 in treating liver cancer, and belongs to the technical field of biological medicines. The invention provides an application of a transferrin receptor 1 inhibitor in preparing anti-liver cancer drugs. The transferrin receptor 1 inhibitor inhibits transcription of the transferrin receptor 1 gene, or inhibits a biological function of the transferrin receptor 1. The transferrin receptor 1 inhibitor is an siRNA. The dosage forms of the transferrin receptor 1 inhibitor medicine comprise tablets, powder, granules, capsules, oral liquid, injection or sustained release preparations. The invention also provides application of the lentivirus generating the transferrin receptor 1RNA interference fragment in preparing anti-liver cancer drugs.
This is a smell, taste and oral health in patients receiving before and after hemodialysis study. End stage renal disease patients who haven't been under hemodialysis will be screened for enrollment at the nephrology department in National Taiwan University Hospital. Patients have to be over 20 years old who are diagnosed with end stage renal disease(eGFR\<15ml/min/1.73m2) but haven't been under hemodialysis yet. Expected 85 patients will be enrolled according to power analysis, those who have the diseases such as Parkinson's disease, hypothyroidism, Sjögren's syndrome, under chemotherapy or radiotherapy, history of head and neck tumour and surgery, and patients who unable to response to evaluate protocal.

We will first use Montreal Cognitive Assessment to screen patient's cognitive function, for those scored 23.5 and higher, a full evaluation will be conducted at two points in before dialysis and afterward. The full evaluation before dialysis include 1.The difference of smell, taste, salivary secretion, oral assessment guide, plaque index and xerostomia on end stage renal disease patients before and after hemodialysis. 2.Investigating the reliability of olfactory identification by using Sniffin'sticks within 2 to 4 hours. 3.Investigating the correlation between taste questionnaire and taste strips. 4.Salivary flow rate. 5.Oral Assessment Guide. 6.Plaque Index. 7.Taste threshold sensitivity.

The evaluation after dialysis involved 1.The olfactory identification 2. Salivary flow 3. Taste threshold sensitivity.For patients who get score lower than 23.5 from Montreal Cognitive Assessment, we'll skip the test of olfactory and taste .Data will be analyzed with descriptive and inferential statistics using R studio statistic software.
The core implementation strategy components are: 1) short video-trainings for clinic personnel (care team staff and providers) on the administration of caregiver-reported screening tools; 2) technical implementation support using an approach comprised of external academic consultants, and internal FQHC personnel to increase inner context capacity, 3) use of a validated clinical screening tool - Pediatric Symptoms Checklist (PSC-17), used in pediatric primary care settings to assess behavioral and social/emotional development. For this study, we will use the PSC tools that are tailored to children ages 0 to 5 years old with the Baby Pediatric Symptomatology Checklist (BPSC) for ages 0 to 18 months, and the Preschool Pediatric Symptom Checklist (PPSC) for ages 18 to 60 months. This screening tools is needed as the PEARLS only assesses ACEs exposure and not mental health symptomatology; and 4) use of a technology based tailored ACEs algorithm that incorporates multiple data sources.
PURPOSE: To obtain a compd. useful to produce a medicine for treating a malign tumor, an inflammatory disease, etc., by removing protective groups from an intermediate compd. in the presence of water, etc. CONSTITUTION: Phenyl glycoside represented by formula I glycosyl is polysaccharide, oligosaccharide or monosaccharide protected with benzyl protective groups, etc., W is an arom. group having a conjugated double bond, R is H, methyl, etc., (p) is 0 or 1, (n) is an integer, X is O, NH, etc., Y is O, NH, etc., and Z is a reactive removable group such as a chloride) is allowed to react with a drug in the presence of an org. base such as triethylamine and a solvent such as acetonitrile or dioxane to form a protected intermediate compd. The protective groups are then removed by hydrolysis with an alkali metallic hydroxide soln. in the presence of methanol, etc., to obtain the objective compd. represented by formula II.
The control program will consist of progressive exercises according to each postoperative day. Two daily sessions with an average duration of 25 min will be performed. In addition to the physiotherapeutic program standardized by the hospital's team of physical therapists, the intervention group will perform physical exercise on a cycle ergometer with CPAP.
Ultrasensitive detection of circulating tumor cells (CTCs) holds significant clinical importance in monitoring metastasis and therapeutic outcomes. In this study, we have developed a novel electrochemical sensing model based on nanomaterials for highly sensitive and specific determination of CTCs. A gold electrode co-modified with Ketjin black (KB) and Au nanoparticles (AuNPs) exhibits exceptional conductivity. By conjugating palladium-iridium cubic nanozyme (Pd-Ir CNE) with antibodies, we have created a detection probe capable of catalyzing hydrogen peroxide (H2O2), thereby amplifying the output signal and resulting in significantly enhanced current on the electrode for detecting CTCs. The constructed immunosensor has achieved a detection limit of 2 cell mL-1 for model MCF-7 cells. Furthermore, the as-constructed electrochemical immunosensor can accurately detect whole blood-spiked target CTCs, showing great promise for clinical applications in early cancer diagnosis and prognosis.
The invention discloses a nano vaccine and a preparation method thereof. Adenine and zinc ions are coordinated and complexed to form a coordination self-assembly carrier, and an antigen and/or an adjuvant can be loaded to prepare the nano vaccine. The preparation method is simple to operate, adopts pure water phase synthesis, and does not generally relate to an organic solvent. The nano vaccine can be loaded with antigen and adjuvant molecules. The main auxiliary material component is adenine, and the biological safety and the compatibility are good. The prepared nano vaccine has the characteristic of pH response, and can be disintegrated to release the loaded drug when the environmental pH value is close to 5. The prepared nano vaccine has uniform particle size and is easy to be taken by DC. The prepared nano vaccine can promote DC maturation and improve the expression of cell surface co-stimulatory molecules. The prepared nano vaccine can obviously improve the cross presentation efficiency of DC to antigen and can effectively activate cellular immunity.
Methylphenidate Transdermal System is supplied in a sealed tray containing 30 individually pouched transdermal systems. See the chart below for information regarding available strengths.

Store at 25° C (77° F); excursions permitted to 15-30° C (59-86° F) [see USP Controlled Room Temperature]. Do not store transdermal systems unpouched. Do not store transdermal systems in refrigerators or freezers.

Once the sealed tray is opened, use contents within 2 months. Apply the transdermal system immediately upon removal from the individual protective pouch. For transdermal use only.

See the Patient Counseling Information (17) for specific disposal instructions for unused or expired Methylphenidate Transdermal System.
Background: Transesophageal echocardiography (TEE) has become a standard intraoperative diagnosis technique for clinical management of patients during cardiac and non-cardiac surgery. Accurate intraoperative diagnosis by TEE improves as image quality improves. Although we recently reported enhanced image quality using a TEE probe with an attached orogastric tube, its clinical significance is still unknown. Also, we are concerned about potential clinical complications including damage to the upper gastrointestinal tract due to its rough surface. Therefore, we devised a new TEE probe cover equipped with a suction catheter and ultrasound gel containing pad that functions as a cushion for preventing surrounding tissue trauma. Our long-term goal is to improve TEE image quality, which will help surgical decision-making with precise assessment. The study population will be elective cardiac cases and liver transplant cases at Henry Ford Hospital. The objective of this grant is to assess the image quality change with our newly designed TEE probe, and its clinical utility on patient care in different types of procedures.

Aim 1. To assess TEE image quality before and after pin-point suctioning with our newly designed TEE probe. We hypothesize that decreasing stomach air between the TEE probe transducer and tissue wall by pin-point suction with our newly designed TEE probe will reduce ultrasound reflection and lead to better image quality.

Aim 2. To evaluate the clinical utility of our newly designed TEE probe cover. We hypothesize our newly designed TEE probe cover will facilitate decision-making for both anesthesiologists and surgeons and it will not increase the occurrence of TEE probe related trauma.
NEW MATERIAL:A novel pyrimidine derivative shown by the formula I (R is hydrocarbon). EXAMPLE:2-Methylthio-4-fluoro-5-trifluoromethyl-6-hydroxypyrimidine. USE:An intermediate for drugs such as antitumor agent, etc. or for agricultural chemicals such as herbicide, etc. Introducing characteristically a 6-hydroxyl group. PREPARATION:An isothiourea derivative shown by the formula II is subjected to ring closure in the presence of a basic catalyst to obtain a novel pyrimidine derivative shown by the formula I . The isothiourea derivative shown by the formula II is obtained from octafluoroisobutene as a raw material.
Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration, or renal failure, can occur with TAFINLAR. 

The incidence and severity of pyrexia are increased when TAFINLAR is administered with trametinib compared with TAFINLAR as a single agent [see Adverse Reactions (6.1)]. 

TAFINLAR Monotherapy (Adult): In the pooled safety population [see Adverse Reactions (6.1)], fever (serious and non-serious) occurred in 30% of patients. Approximately 13% of these patients experienced 3 or more discrete episodes. Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills occurred in 6% of patients.

TAFINLAR Administered with Trametinib (Adult): In the pooled safety population [see Adverse Reactions (6.1)], fever occurred in 58% of patients. Serious febrile reactions and fever of any severity complicated by hypotension, rigors or chills, dehydration or renal failure occurred in 5% of patients. Fever was complicated by hypotension in 4%, dehydration in 3%, syncope in 2%, renal failure in 1%, and severe chills/rigors in < 1% of patients.

TAFINLAR Administered with Trametinib (Pediatric): In the pooled safety population [see Adverse Reactions (6.1)], pyrexia occurred in 66% of patients.

Withhold TAFINLAR when used as monotherapy, and both TAFINLAR and trametinib when used in combination, if the patient’s temperature is ≥ 100.4°F. In case of recurrence, therapy can also be interrupted at the first symptom of pyrexia [see Adverse Reactions (6.1)]. Fever may be complicated by hypotension, rigors or chills, dehydration, or renal failure. Evaluate for signs and symptoms of infection and monitor serum creatinine and other evidence of renal function during and following severe pyrexia. If appropriate, TAFINLAR, or both TAFINLAR and trametinib when used in combination, may be restarted if the patient has recovered from the febrile reaction for at least 24 hours, either at the same or lower dose [see Dosage and Administration (2.4)]. Administer antipyretics as secondary prophylaxis when resuming TAFINLAR if patient had a prior episode of severe febrile reaction or fever associated with complications. Administer corticosteroids (e.g., prednisone 10 mg daily) for at least 5 days for second or subsequent pyrexia if temperature does not return to baseline within 3 days of onset of pyrexia, or for pyrexia associated with complications, such as dehydration, hypotension, renal failure, or severe chills/rigors, and there is no evidence of active infection.